GG
REGN icon

Gleason Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Gleason Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-55
Closed -$48.3K – 215
2023
Q4 		$48.3K Hold
55
– – 0.01% 117
2023
Q3 		$45.3K Hold
55
– – 0.01% 122
2023
Q2 		$39.5K Hold
55
– – 0.01% 124
2023
Q1 		$45.2K Hold
55
– – 0.01% 120
2022
Q4 		$39.7K Hold
55
– – 0.01% 123
2022
Q3 		$38K Hold
55
– – 0.01% 123
2022
Q2 		$33K Hold
55
– – 0.01% 129
2022
Q1 		$38K Hold
55
– – 0.01% 128
2021
Q4 		$35K Hold
55
– – 0.01% 123
2021
Q3 		$33K Hold
55
– – 0.01% 127
2021
Q2 		$31K Buy
+55
New +$27.9K 0.01% 130

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Gleason Group's REGN Position: Q1 2024 in Review

Gleason Group sold out of Regeneron Pharmaceuticals (REGN) in Q1 2024, closing a stake of 55 shares — an estimated $48.3K sold.

Gleason Group first reported a position in REGN in Q2 2021 and held it in 11 quarters. The position peaked at $48.3K in Q4 2023. 1,312 funds tracked by Wall St. Rank hold REGN as of Q1 2024.

  • Gleason Group reported no remaining Regeneron Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Gleason Group sold 55 Regeneron Pharmaceuticals shares in Q1 2024, an estimated $48.3K.
  • Gleason Group first reported a position in Regeneron Pharmaceuticals in Q2 2021 and held it in 11 quarters.
  • Gleason Group's Regeneron Pharmaceuticals position peaked at $48.3K in Q4 2023.
  • 1,312 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2024.

Based on Gleason Group's 13F filing for Q1 2024, filed 12 Apr 2024.